AGILENT TECHNOLOGIES, INC. A
AGILENT TECHNOLOGIES, INC. is a laboratory analytical instruments issuer listed as A on NYSE. This free Atlas page links SEC CIK 1090872, Nasdaq Trader and TradingView NYSE:A, related symbols and the workstation route before a full report is run.
A public profile
Laboratory analytical instruments issuer. Atlas tracks A through its NYSE listing record, chart route and source links.
A trades on NYSE. SEC CIK 1090872. Chart route NYSE:A.
Nasdaq Trader is the listing identity source for AGILENT TECHNOLOGIES, INC.. Atlas files A under USA Stocks and Technology Stocks for browsing. The canonical public URL is /stocks/A/. The workstation link below opens the fuller research run.
Market Wit preview
Agilent walked into June with the rare kind of filing rail that says more about the business than any slogan could. The latest 10-Q puts revenue from contracts with customers at $1.83B for the period ending 2026-04-30, with net income attributable to parent of $339.0M and diluted EPS of $1.20. This is not a mystery-box equity story; it is a company selling instruments, remarketed instruments, third-party products, services, spare parts, consumables, reagents, software licences and other lab-adjacent necessities. In plain English, the customer does not just buy the machine and vanish. There is installation, service, parts, subscriptions, software and the long practical afterlife of scientific kit. Markets often prefer a grand theme. The filing offers...
Run the full workstation report for the complete source rail, saved history, export controls, and the full Market Wit file for A.
What changed for AGILENT TECHNOLOGIES, INC. today
Agilent Technologies, Inc. enters this daily file with earnings and filing evidence doing the heavy lifting. The latest supplied 10-Q, filed on 2026-06-01 for the period ending 2026-04-30, reports revenue from contracts with customers of $1.83B, net income attributable to parent of $339.0M, operating income of $399.0M and diluted earnings per share of $1.20. That is the centre of the story because it gives readers a filed operating picture rather than a market mood.
The business rail matters because Agilent is not described here as a single-product story. The 10-Q evidence says instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation revenue includes contract and per-incident services, companion diagnostics, contract development and manufacturing, spare parts, consumables, reagents, vacuum pumps, subscriptions, software licences and associated services. The company also receives cash from customers for products and related installation and services before control transfers. The plain mechanism is equipment plus service life, with the customer relationship extending beyond the first shipment.
The balance sheet and cash figures add weight. The 10-Q for the period ending 2026-04-30 lists assets of $13.06B, liabilities of $5.94B, stockholders' equity attributable to parent of $7.12B, cash and cash equivalents of $1.81B, and net cash provided by operating activities of $545.0M. Payments to acquire property, plant and equipment were $169.0M, research and development expense was $126.0M, inventory, net, was $1.09B, and the increase in inventories was $85.0M. The warranty line is also visible: standard product warranty accrual, increase for warranties issued, was $28.0M. Diluted weighted average shares outstanding were 283.0M.
The chart route is not supplied in this evidence pack, so there is no sourced basis here for price levels, candle patterns, moving averages or trading ranges. The source route is SEC EDGAR: the 10-Q, two 8-K filings, ownership forms, the filing index, submissions JSON and companyfacts JSON. That makes this a filing-led market story. The mechanism to watch inside the supplied rail is not a guessed technical setup, but how reported revenue, operating income, cash generation, inventory, capex, R&D and management transition fit together.
What changed in the named developments is also official and specific. The 2026-05-27 SEC EDGAR 8-K says Agilent issued its press release announcing second fiscal quarter results for the quarter ended 2026-04-30. It also says Gonsalves will remain employed as Vice President, Finance to provide transitional assistance through January 2027, with the exact date to be determined, and that Downs, age 45, previously served as Vice President, Finance, Technical and SEC Reporting at Baker Hughes from April 2024 to May 2026. The 2026-05-04 SEC EDGAR 8-K says Bret DiMarco will remain employed as a Special Advisor through 2026-12-01, and that Agilent announced Michael Buckner as Chief Legal Officer.
The limits are clean. The rail supplies official filings and parsed financial figures, but it does not supply guidance, segment pressure, dividend data, buyback figures, analyst estimates, price action or a chart source. That absence is part of the research finding. The current file can say Agilent has filed revenue, profit, cash, inventory, capex, R&D, warranty accrual and succession facts; it cannot turn those facts into a price call or a broader market claim without a source that is not present here.
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
Atlas has no approved static OHLC cache attached for A yet, so the profile renders the verified TradingView chart route directly and keeps the full-chart link as fallback.
Run an Atlas research workflow on A
FreedomCore Atlas operates research workstation templates for company snapshots, DCF, LBO, KYC, NAV tie-outs, and council-grade equity briefs. Each workflow uses public-source filings and structured prompts.
Open Atlas workstation ->Save A research and exports
Free Atlas users can run full browser research reports from the workstation. Atlas Pro adds 25 custom runs a day, saved research history, email delivery, PDF/CSV exports, and a 25-symbol watchlist. £12/mo founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
A FAQ
What is AGILENT TECHNOLOGIES, INC. (A)?AGILENT TECHNOLOGIES, INC. is a laboratory analytical instruments issuer listed as A on NYSE. This free Atlas page links SEC CIK 1090872, Nasdaq Trader and TradingView...
AGILENT TECHNOLOGIES, INC. is a laboratory analytical instruments issuer listed as A on NYSE. This free Atlas page links SEC CIK 1090872, Nasdaq Trader and TradingView NYSE:A, related symbols and the workstation route before a full report is run.
What does Atlas show for A?The A page gives the free Atlas profile for AGILENT TECHNOLOGIES, INC.: listing identity, chart route, related symbols, source authority and the workstation route. The...
The A page gives the free Atlas profile for AGILENT TECHNOLOGIES, INC.: listing identity, chart route, related symbols, source authority and the workstation route. The chart route is NYSE:A; the stable page route is /stocks/A/. Visible source links include SEC EDGAR CIK 1090872, Nasdaq Trader and TradingView NYSE:A. Atlas files A under USA Stocks and Technology Stocks for browsing.
How often is the A page updated?The /stocks/A/ URL is stable. Atlas updates the free A page when the symbol-universe record, listing identity, source links, chart route, related-symbol links or...
The /stocks/A/ URL is stable. Atlas updates the free A page when the symbol-universe record, listing identity, source links, chart route, related-symbol links or published public answer changes.
Which sources does Atlas use for A?For A, Atlas starts with SEC EDGAR CIK 1090872, Nasdaq Trader and TradingView NYSE:A. The SEC CIK 1090872 route is the issuer filing anchor. Nasdaq Trader confirms the...
For A, Atlas starts with SEC EDGAR CIK 1090872, Nasdaq Trader and TradingView NYSE:A. The SEC CIK 1090872 route is the issuer filing anchor. Nasdaq Trader confirms the listed-symbol identity used by the public directory. NYSE:A is the chart route shown on the free page. Full workstation reports may add fresh filings, issuer documents, holdings, news, macro context or model-reviewed notes when available.
Can Atlas run a full research brief on A?Yes. The workstation can open A, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open A, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this A page investment advice?No. The A page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a buy or sell instruction, or a promise...
No. The A page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a buy or sell instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-06-20. Browse FreedomCore Atlas research notes →